Novartis Signs $7.8 Billion Drug Deal With Chinese Startup

Novartis agreed to a drug-development deal worth $7.8 billion with a Chinese biotech startup, Axios reported, in one of the largest publicly disclosed pharma transactions involving a China-based counterparty.